subscribe Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Subscribe now
Picture: 123RF/PEOGEO
Picture: 123RF/PEOGEO

GLP-1 drugs have grown in popularity and Aspen is betting on contracts for the medications to boost future earnings. To discuss the evolution of the highly effective diabetes and obesity drugs, Business Day TV sat down with Aspen’s Stavros Nicolaou.

Companies in this Story

subscribe Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Subscribe now

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.